The US FDA will "assess," rather than "review," generic drug applications going forward as part of a larger effort to streamline their evaluations and increase competition in the market.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?